Anagliptin
CAY-36188-5 5 mg
Data Sheet: 
SDS:
SDS:
CAS
739366-20-2
Formulation
A solid
Purity
≥95%
MW
383,5
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A DPP-4 inhibitor (IC50 = 3.8 nM); selective for DPP-4 over DPP-8 and DPP-9 (IC50s = 68 and 60 nM, respectively); dietary administration decreases plasma DPP-4 activity, increases plasma GLP-1 levels, suppresses food intake and body weight gain, ameliorates insulin resistance, and improves glucose tolerance in wild-type and glucokinase knockout mouse models of high-fat diet-induced diabetes at 0.05 and 0.3% w/w; decreases hepatic lipid and M1 macrophage accumulation and prevents hepatic fibrosis and steatohepatitis in mice fed a high-cholesterol high-fat diet or a CDAHF diet; reduces atherosclerotic lesion size in an Apoe-/- mouse model of atherosclerosis
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
